Open AccessDecode: COVID-19 Associated Mucormycosis
Author(s) -
Priyanka Yadav,
Sangeeta Mahaur,
Raj Prasad,
Manoj Míshra
Publication year - 2022
Publication title -
scholars academic journal of pharmacy
Language(s) - English
Resource type - Journals
eISSN - 2347-9531
pISSN - 2320-4206
DOI - 10.36347/sajp.2022.v11i03.001
Subject(s) - mucormycosis , medicine , pneumonia , covid-19 , intensive care medicine , warning signs , coronavirus , disease , diabetes mellitus , infectious disease (medical specialty) , surgery , transport engineering , engineering , endocrinology
The coronavirus infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be related with a wide range of disease and ranging from mild to life-threatening pneumonia. Patients with COVID-19 have higher susceptibility to fungal coinfections. Mucormycosis is a rare and-threatening fungal infection. Mucormycosis is more common in immunocompromised individuals, and patients with uncontrolled diabetes. COVID-19 associated mucormycosis usually developed 10-14 days after hospitalization. A high number of suspicion diagnosis and aggressive management is required to improve outcomes of the therapy. Awareness of warning symptoms and signs play an important role for the identification of the mucormycosis.